Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Isis Pharmaceuticals to Present at the 2009 Canaccord Adams Cardiovascular Conference on November 10, 2009

Isis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at Canaccord Adams' 2009 Cardiovascular Conference on Tuesday, November 10, 2009, at 11:00 a.m. PT at the Nikko Hotel in San Francisco.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. 

Source: Isis Pharmaceuticals, Inc.

You can discuss more about Cardiology and related topics in our Cardiology Group.